title: HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.
abstract: The expression of human leukocyte antigen-G (HLA-G) and HLA class II protein was studied by immunohistochemical staining of lymph nodes from 148 patients with diffuse large B-cell lymphoma (DLBCL) and related to the clinical course of the disease. Negative HLA-G expression was associated with a lower probability of achieving a complete remission (p = 0.04). Patients with negative HLA-G expression tended towards a lower 3-year overall survival (OS) rate compared to those with positive expression of HLA-G (p = 0.08). When restricting the analysis to patients receiving chemotherapy with rituximab, the estimated 3-year OS rate of patients with positive HLA-G expression was 73.3 % compared with 47.5 % (p = 0.03) in those with negative expression. Patients with negative HLA class II expression presented a lower 3-year OS rate compared to subjects with positive expression (p = 0.04). The loss of HLA class II expression (p = 0.05) and belonging to the intermediate high/high IPI risk group (p = 0.001) independently increased the risk of death. HLA class II expression also retained its prognostic value in patients receiving rituximab; the 3-year OS rate was 65.3 % in patients with positive HLA class II expression versus 29.6 % (p = 0.04) in subjects that had loss of HLA class II expression. To our knowledge, for the first time, the expression of HLA-G protein in DLBCL and its association with the clinical course of the disease was demonstrated. Moreover, the link between losing HLA class II protein expression and poor survival of patients treated with immunochemotherapy was confirmed.
authors.affiliation: Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
authors.forename: Dorota
authors.initials: D
authors.lastname: Jesionek-Kupnicka
authors.affiliation: Department of Chemotherapy, Copernicus Memorial Hospital, Lodz, Poland.
authors.forename: Marcin
authors.initials: M
authors.lastname: Bojo
authors.affiliation: Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
authors.forename: Monika
authors.initials: M
authors.lastname: Prochorec-Sobieszek
authors.affiliation: Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Szumera-Ciećkiewicz
authors.affiliation: Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Jabłońska
authors.affiliation: Department of Chemotherapy, Copernicus Memorial Hospital, Lodz, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Kalinka-Warzocha
authors.affiliation: Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
authors.forename: Radzisław
authors.initials: R
authors.lastname: Kordek
authors.affiliation: Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Młynarski
authors.affiliation: Department of Hematology, Medical University of Lodz, Lodz, Poland.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.affiliation: Department of Hematology, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14, 02-776, Warsaw, Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Warzocha
authors.affiliation: Department of Hematology, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14, 02-776, Warsaw, Poland. ewamaranda@wp.pl.|Department of Hematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland. ewamaranda@wp.pl.
authors.forename: Ewa
authors.initials: E
authors.lastname: Lech-Maranda
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D059951:HLA-G Antigens / Q000276:immunology* / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology* / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011336:Probability; D011379:Prognosis; D012044:Regression Analysis; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D059951:HLA-G Antigens; D000949:Histocompatibility Antigens Class II; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Diffuse large B-cell lymphoma; Human leukocyte antigen-G; Immunohistochemistry; Major histocompatibility class II; Outcome